KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
15.51
+0.50 (3.33%)
At close: Feb 11, 2026, 4:00 PM EST
15.54
+0.03 (0.19%)
Pre-market: Feb 12, 2026, 8:16 AM EST
KalVista Pharmaceuticals Revenue
KalVista Pharmaceuticals had revenue of $13.69M in the quarter ending September 30, 2025.
Revenue (ttm)
$1.43M
Revenue Growth
n/a
P/S Ratio
549.77
Revenue / Employee
$5,281
Employees
270
Market Cap
783.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | - | - | - |
| Apr 30, 2024 | - | - | - |
| Apr 30, 2023 | - | - | - |
| Apr 30, 2022 | - | - | - |
| Apr 30, 2021 | - | - | - |
| Apr 30, 2020 | 12.69M | -3.44M | -21.31% |
| Apr 30, 2019 | 16.13M | 7.73M | 92.13% |
| Apr 30, 2018 | 8.39M | 6.89M | 458.11% |
| Apr 30, 2017 | 1.50M | -629.00K | -29.49% |
| Apr 30, 2016 | 2.13M | 2.10M | 7,255.17% |
| Dec 31, 2015 | 29.00K | - | - |
| Dec 31, 2014 | 29.00K | -386.00K | -93.01% |
| Dec 31, 2013 | 415.00K | -1.12M | -73.02% |
| Dec 31, 2012 | 1.54M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 393.44M |
| Maravai LifeSciences Holdings | 192.44M |
| Arbutus Biopharma | 14.61M |
| Janux Therapeutics | 10.00M |
| Upstream Bio | 2.80M |
| YD Bio | 510.36K |
KALV News
- 17 hours ago - KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion - Seeking Alpha
- 9 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug - Benzinga
- 4 weeks ago - KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results - Business Wire
- 7 weeks ago - KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire
- 2 months ago - KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 months ago - KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results - Business Wire